Item 8.01 Other Events.

Story continues below

On April 12, 2018, the Company announced positive interim data for ABI-H0731, the Company’s lead product candidate from its hepatitis B virus (HBV)-cure program, from the Phase 1a and 1b portion of its clinical study, which assessed the safety, tolerability and pharmacokinetics, as well as antiviral efficacy of ABI-H0731, a novel, oral Core protein Allosteric Modifier (CpAM) with selective and potent activity against all major HBV genotypes, in patients with chronic HBV infection.

The interim data, which is also being presented on a poster at The International Liver Congress™, the Annual Meeting of the European Association for the Study of the Liver (EASL), includes the interim data from the ongoing Phase 1b antiviral efficacy study and a recently completed Phase 1a safety and pharmacokinetic (PK) study of ABI-H0731. To date, two cohorts (100 mg and 200 mg) of HBV patients have completed dosing in the Phase 1b trial, in addition to three (100 mg, 200 mg and 300 mg) additional cohorts in a Phase 1a study in healthy volunteers. A third HBV patient cohort receiving 300 mg is ongoing, though only initial results are reported in the EASL poster. Two HBeAg negative patients have also been treated at 400 mg.

The Phase 1b patient study enrolled both HBeAg positive and negative patients. Potent antiviral activity was observed across patient cohorts in a dose dependent manner. Specifically, in the ongoing 300 mg dose cohort, the mean overall decline from baseline is currently ≥2.8 log IU/mL, with ≥2.9 and 2.5 log IU/mL mean declines in HBeAg positive and negative patients, respectively. Maximal viral load declines of 3.6 to 4.0 log IU/mL were observed in certain HBeAg negative patients treated at all dose levels (100 mg to 400 mg). The Company intends to report complete results from this study at a scientific conference later in 2018.

Across all cohorts in the Phase 1a and Phase 1b studies, ABI-H0731 was generally safe and well tolerated. No serious adverse effects or dose-limiting toxicities were identified, and there was no pattern of treatment emergent clinical or laboratory abnormalities observed. Among the 62 patients and volunteers treated, all treatment emergent adverse events (TEAEs) were observed to be minor (Grade 1), with the exception of an isolated Grade 3 rash at the 400 mg dose that resolved rapidly without intervention other than treatment discontinuation. To date, no other treatment discontinuations have occurred in these studies.

The interim study results support the advancement of ABI-H0731 into Phase 2a combination studies using a 300 mg dose expected to begin this summer. The first study will enroll HBeAg positive patients on standard of care nucleos(t)ide therapy with fully suppressed viral loads. Patients will continue their nucleos(t)ide therapy and be randomized to either placebo or ABI-H0731 for six months. This study is designed to demonstrate that ABI-H0731 can inhibit the generation of cccDNA molecules by showing a decline in the surrogate markers of cccDNA. A second Phase 2a study will enroll treatment naïve HBeAg positive patients and is designed to compare the antiviral effectiveness of standard of care nucleoside therapy alone compared to standard of care in combination with ABI-H0731 for six months. The Company anticipates results from these studies during the first half of 2019.

Forward-Looking Statements

The information in this Current Report on Form 8-K contains forward-looking statements regarding future events, including statements about the clinical and therapeutic potential of ABI-H0731 and the Company’s development programs, interim data’s reliability to predict completed clinical study results, the initiation, progress and results of the Company’s ongoing and planned clinical trials, and the timing of these events. Certain forward-looking statements may be identified by reference to a future period or periods or by use of forward-looking terminology such as “plan,” “intends,” “designed” or “developing.” The Company intends such forward-looking statements to be covered by the safe harbor provisions contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. More information about the risks and uncertainties faced by the Company are more fully detailed under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2017 filed with the Securities and Exchange Commission. Except as required by law, the Company assumes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.


Assembly Biosciences, Inc. is a biotechnology company. The Company is engaged in developing approximately two platform programs, such as a class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection, and a class of oral biological therapeutics, which are designed to restore health to a dysbiotic microbiome. It has discovered various core protein Allosteric Modulators (CpAMs), which are small molecules that directly target and allosterically modulate a number of Hemoglobin C functions. The Microbiome Program consists of an integrated platform that includes a strain identification and selection process, methods for strain isolation and growth under current good manufacturing practice (cGMP) conditions, and a delivery system, GEMICEL, which allows for targeted oral delivery of live biologic and conventional therapies to the lower gastrointestinal tract. The lead program from this platform, AB-M101, is in development for the treatment of C. difficile-infections.

An ad to help with our costs